Omeros has launched two Phase 1b clinical trials to test its experimental therapy OMS906 in people with paroxysmal nocturnal…
Marisa Wexler MS
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler MS
Early screening for paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia — two bone marrow disorders that often occur together —…
People with paroxysmal nocturnal hemoglobinuria (PNH) newly treated with Empaveli (pegcetacoplan) are more likely to see their hemoglobin levels rise…
ARO-C3, an experimental treatment being developed for paroxysmal nocturnal hemoglobinuria (PNH) and other disorders mediated by the complement system, appears…